Virax Biolabs Group to initiate Virax Immune Covid-19 Analytical Performance Study

Virax Biolabs Group Limited (Virax), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced the initiation of its Virax Immune Covid-19 Analytical Performance Study scheduled to take place through Q4 of this year and finishing in Q1 of next year. The Analytical Performance Study will evaluate the technical performance of the Virax Immune Covid-19 Flow Cytometry Kit and will include specimens from 96 healthy volunteers.

Virax Immune is a proprietary T-Cell In-Vitro Diagnostic (IVD) test technology being developed with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. Unlike antibodies, T-Cells coordinate the immune system against major global viral attacks and have been shown to provide a level of protection against Covid-19 and its variants that is more robust and long-lasting than an antibody mediated response. Their detection can give an indication of inherent protection from disease for those yet to be infected and may be useful to determine the degree of long-term protection an individual has after recovering from major global viral threats.

The first test being developed using the Virax Immune platform is for immunity related to Covid-19. Using data from the IVD test, our proprietary mobile application would be set up to offer an algorithmic immunological profile for patients, which would provide information such as if vaccination has been successful in providing protection or if additional vaccination boosters are required. Additional tests may be developed in the future for new global pandemics and for such viruses as Human Papillomavirus (better known as HPV), malaria, hepatitis B, and Herpes (better known as HSV-1).

Our T-Cell tests have been designed to be as affordable and scalable as possible, by avoiding the requirement for complex processes and expensive lab equipment. The 'lab agnostic' nature of the tests is intended to result in penetration of both established and emerging markets in the near term across a variety of pathogens. Virax's chairman of the board of directors and chief executive officer, James Foster, commented "We are excited to be taking the next step to bring Virax Immune to the market by initiating our Covid-19 analytical performance study.

Virax Immune is a cutting edge immunological diagnostic profiling technique that may revolutionize how we manage viral outbreaks. I look forward to providing our investors with additional updates as we progress." Founded in 2013, Virax Biolabs is an Innovative Biotechnology firm focused on the diagnosis of and the detection of immune responses to viral diseases.